Display options
Share it on

Cancer Cell Int. 2021 Sep 16;21(1):493. doi: 10.1186/s12935-021-02071-y.

High expression of oncogene cadherin-6 correlates with tumor progression and a poor prognosis in gastric cancer.

Cancer cell international

Zongxian Zhao, Shuliang Li, Shilong Li, Jun Wang, Hai Lin, Weihua Fu

Affiliations

  1. Tianjin Medical University General Hospital, No. 154 Anshan Road, Heping District, Tianjin, China. [email protected].
  2. Department of Gastrointestinal Surgery, The Second People's Hospital of Liaocheng, Liaocheng, Shangdong, China. [email protected].
  3. Tianjin Medical University General Hospital, No. 154 Anshan Road, Heping District, Tianjin, China.
  4. Tianjin Medical University General Hospital, No. 154 Anshan Road, Heping District, Tianjin, China. [email protected].

PMID: 34530820 PMCID: PMC8447617 DOI: 10.1186/s12935-021-02071-y

Abstract

BACKGROUND: Gastric cancer (GC) is one of the most common and fatal cancers worldwide. Effective biomarkers to aid the early diagnosis of GC, as well as predict the course of disease, are urgently needed. Hence, we explored the role and function of cadherin-6 (CDH6) in the diagnosis and prognosis of gastric cancer.

METHODS: The expression levels of CDH6 in cancerous and normal gastric tissue were analyzed using multiple public databases. Gene set enrichment analysis (GSEA) was performed using The Cancer Genome Atlas (TCGA) dataset. The diagnostic efficiency of CDH6 expression in GC patients was determined through receiver operating characteristic (ROC) curve analysis. The associations between clinical variables and CDH6 expression were evaluated statistically, and the prognostic factors for overall survival were analyzed by univariate and multivariate Cox regression. 44 GC tissue samples, 20 donor-matched adjacent normal tissue samples, and associated detailed clinical information, were collected from the Tianjin Medical University General Hospital. CDH6 expression levels were determined for further validation.

RESULTS: CDH6 was upregulated in GC samples compared to normal gastric tissue. Furthermore, GSEA identified the tricarboxylic acid (TCA) cycle, extracellular matrix (ECM) receptor interaction, glyoxylate and dicarboxylate metabolism, oxidative phosphorylation, and the pentose phosphate pathway as differentially enriched in GC tissue samples. According to the area under the ROC curve (AUC) values (AUC = 0.829 in the TCGA and 0.966 in the GSE54129 dataset), CDH6 expression was associated with high diagnostic efficacy. Patients with high CDH6 levels in their GC tissues had a higher T number (according to the TNM classification) and a worse prognosis than those with low CDH6 expression. Univariate and multivariate Cox regression analysis showed that CDH6 was an independent risk factor for overall survival (univariate: HR = 1.305, P = 0.002, multivariate: HR = 1.481, P < 0.001).

CONCLUSION: CDH6 was upregulated in GC, and high CDH6 expression was indicative of a higher T number and a worse prognosis. Therefore, CDH6 represents a potentially independent molecular biomarker for the diagnostic and prognostic prediction of GC.

© 2021. The Author(s).

Keywords: Cadherin-6; Gastric cancer; Oncogene; Prognosis; Tumor progression

References

  1. Development. 1998 Mar;125(5):803-12 - PubMed
  2. Oncogenesis. 2017 Dec 22;6(12):402 - PubMed
  3. Am J Transl Res. 2020 Jun 15;12(6):3057-3067 - PubMed
  4. Cell Death Differ. 2011 Sep;18(9):1470-7 - PubMed
  5. Pathol Res Pract. 2019 May;215(5):1038-1048 - PubMed
  6. Int J Mol Sci. 2019 Jul 09;20(13): - PubMed
  7. World J Gastroenterol. 2018 Jul 14;24(26):2818-2832 - PubMed
  8. Tumour Biol. 2017 Jul;39(7):1010428317714626 - PubMed
  9. Breast Cancer Res. 2001;3(5):289-93 - PubMed
  10. Cells. 2019 Sep 20;8(10): - PubMed
  11. Eur J Cancer. 2011 Apr;47(6):934-45 - PubMed
  12. Mol Cell Neurosci. 2008 Sep;39(1):95-104 - PubMed
  13. Med Sci Monit. 2019 May 13;25:3537-3541 - PubMed
  14. Cancer Discov. 2017 Sep;7(9):1030-1045 - PubMed
  15. Cell Mol Life Sci. 2019 Apr;76(7):1299-1317 - PubMed
  16. Int J Mol Sci. 2020 Oct 15;21(20): - PubMed
  17. Cancer Manag Res. 2019 Dec 13;11:10477-10486 - PubMed
  18. PeerJ. 2018 Jul 2;6:e5180 - PubMed
  19. Front Pharmacol. 2018 Dec 05;9:1421 - PubMed
  20. FEBS Lett. 2012 Mar 23;586(6):924-33 - PubMed
  21. Epigenetics. 2016 Nov;11(11):780-790 - PubMed
  22. CA Cancer J Clin. 2021 May;71(3):209-249 - PubMed
  23. World J Surg Oncol. 2018 Jun 19;16(1):114 - PubMed
  24. J Mol Biol. 2000 Jun 9;299(3):551-72 - PubMed
  25. Lancet Oncol. 2008 Mar;9(3):279-87 - PubMed
  26. Oncotarget. 2016 Oct 25;7(43):69871-69882 - PubMed
  27. Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50 - PubMed
  28. Oncol Lett. 2018 May;15(5):7415-7422 - PubMed
  29. Oncol Lett. 2018 Jun;15(6):9498-9506 - PubMed
  30. Nat Rev Genet. 2007 May;8(5):341-52 - PubMed
  31. JAMA Oncol. 2015 Apr;1(1):23-32 - PubMed
  32. Cancer Commun (Lond). 2019 Apr 29;39(1):22 - PubMed
  33. Trends Cell Biol. 2014 Sep;24(9):524-36 - PubMed
  34. Oncogene. 2017 Feb 2;36(5):667-677 - PubMed
  35. Bioessays. 1992 Nov;14(11):743-8 - PubMed

Publication Types